公开(公告)号：EP1083168B1

公开(公告)日：2003-10-22

申请号：EP99921247.5

申请日：1999-05-25

申请人： TAISHO PHARMACEUTICAL CO., LTD ,  Sato, Fumie

发明人： SATO, Fumie ,  TANAMI, Tohru ,  KAMEO, Kazuya ,  YAMADA, Kenji ,  OKUYAMA, Shigeru ,  ONO, Naoya

IPC分类号： C07C405/00 ,  A61K31/557

CPC分类号： A61K31/5575 ,  A61K31/557 ,  C07C405/00 ,  Y10S514/923

摘要： A prostaglandin derivative represented by formula (I) wherein X represents a halogen atom, n is an integer of 1 to 5, R represents a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted with a C1-4 alkyl group, a C4-13 cycloalkylalkyl group, a C5-10 alkyl group, a C5-10 alkenyl group, a C5-10 alkynyl group or a bridged cyclic hydrocarbon group, R represents a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl, or a pharmaceutically acceptable salt thereof.

公开(公告)号：EP1083168A1

公开(公告)日：2001-03-14

申请号：EP99921247.5

申请日：1999-05-25

申请人： TAISHO PHARMACEUTICAL CO., LTD ,  Sato, Fumie

发明人： SATO, Fumie ,  TANAMI, Tohru ,  KAMEO, Kazuya ,  YAMADA, Kenji ,  OKUYAMA, Shigeru ,  ONO, Naoya

IPC分类号： C07C405/00 ,  A61K31/557

CPC分类号： A61K31/5575 ,  A61K31/557 ,  C07C405/00 ,  Y10S514/923

摘要： A prostaglandin derivative represented by formula (I) wherein X represents a halogen atom, n is an integer of 1 to 5, R 1 represents a C 3-10 cycloalkyl group, a C 3-10 cycloalkyl group substituted with a C 1-4 alkyl group, a C 4-13 cycloalkylalkyl group, a C 5-10 alkyl group, a C 5-10 alkenyl group, a C 5-10 alkynyl group or a bridged cyclic hydrocarbon group, R 2 represents a hydrogen atom, a C 1-10 alkyl group or a C 3-10 cycloalkyl, or a pharmaceutically acceptable salt thereof.

公开(公告)号：EP1330240A2

公开(公告)日：2003-07-30

申请号：EP01968558.5

申请日：2001-09-06

申请人： MCW Research Foundation ,  Taisho Pharmaceutical Co. Ltd.

发明人： ROMAN, Richard, J. ,  HARDER, David, R. ,  MIYATA, Noriyuki ,  SATO, Masakazu ,  KAMEO, Kazuya ,  OKUYAMA, Shigeru

IPC分类号： A61K31/00 ,  A61K31/155 ,  A61K31/145 ,  A61K31/20 ,  A61K31/4192 ,  A61K31/4174 ,  A61K39/395 ,  A61K48/00 ,  A61P9/10 ,  A61P31/00 ,  A61P25/00 ,  A61P25/06 ,  A61P25/28

CPC分类号： A61K31/15 ,  A61K31/20 ,  A61K31/4164 ,  A61K31/4192 ,  A61K48/00

摘要： A method for treating cerebral vascular diseases in a human or non-human animal is disclosed. The method involves inhibiting 20-HETE synthesizing enzyme activity sufficiently to increase or prevent a decrease in cerebral blood flow in the human or non-human animal. This can be obtained by treating the animal with inhibitors of CYP4A or CYP4F family of enzymes, such as HET0016, 17-ODYA (17-octadecynoic acid), DDMS (dibromododecenyl methylsulfimide), 1-ABT (1-aminobenzotriazole) and miconazole, or with an antibody to 20-HETE synthetizing enzyme or with an antisense oligo-nucleotide directed against 5' end of CYP4A1, CYP4A2, CYP4A11, CYP4F2 or CYP4F3.

公开(公告)号：EP1475102A1

公开(公告)日：2004-11-10

申请号：EP03705219.8

申请日：2003-02-17

申请人： TAISHO PHARMACEUTICAL CO., LTD

发明人： MIYATA, Noriyuki ,  OKUYAMA, Shigeru ,  TAKAHASHI, Teisuke ,  TAKAHASHI, Kenzo

IPC分类号： A61K45/00 ,  A61K31/136 ,  A61P9/12 ,  A61P43/00

CPC分类号： A61K31/136

摘要： A therapeutic agent for hypertension, which comprises as an active ingredient a compound capable of inhibiting Na + /Ca 2+ exchanger 1.

摘要翻译： 高血压治疗剂，其含有能够抑制Na + / Ca 2+交换体1的化合物作为活性成分。

公开(公告)号：EP1425258A2

公开(公告)日：2004-06-09

申请号：EP02761383.5

申请日：2002-09-09

申请人： TAISHO PHARMACEUTICAL CO., LTD ,  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： FALCK, John R. ,  MIYATA, Noriyuki ,  ONO, Naoya ,  CHONAN, Tomomichi ,  HIRANO, Hitomi ,  TODA, Yoshihisa ,  TANAMI, Tohru ,  OKUYAMA, Shigeru

IPC分类号： C07C59/00 ,  C07C255/00 ,  A61K31/42 ,  A61K31/425 ,  C07D277/00

CPC分类号： C07D257/04 ,  C07C33/044 ,  C07C33/423 ,  C07C33/426 ,  C07C59/42 ,  C07C59/46 ,  C07C59/60 ,  C07C69/708 ,  C07C235/28 ,  C07C255/15 ,  C07C259/06 ,  C07C309/10 ,  C07C309/20 ,  C07C309/23 ,  C07C309/24 ,  C07C309/68 ,  C07C311/17 ,  C07C311/51 ,  C07C317/44 ,  C07C323/52 ,  C07C323/66 ,  C07C2601/08 ,  C07C2601/14 ,  C07D277/34

摘要： A hydroxyeicosenoic acid analog represented by the following Formula (I), the bond represents a cis-vinylene group or an ethynylene group; Y represents CH2, O or S(O)p wherein p is 0, 1 or 2; m represents an integer of 1 to 4 inclusive; n represents an integer of 0 to 3 inclusive; the sum of m and n is an integer of 3 to 7 inclusive; R1 represents a C1-4 alkyl group or a C3-8 cycloalkyl group; R2 represents a hydrogen atom or a methyl group; R3 represents COR4, a nitrile group, a halogen atom, a tetrazole group or a thiazolidinedione group; R4 represents OR6, NHR6, N(OH)R?6, NHSO2R5¿, glycerol or functionalized glycerols; R5 represents a C¿1-15? alkyl group, a C6-10 aryl group or a C7-14 aryl group substituted with alkyl groups, halogens or amino groups; R?6¿ represents a hydrogen, a C¿1-10? alkyl group or a C1-10 alkyl group substituted with a hydroxyl group, or a pharmaceutically acceptable salt or hydrate thereof. The compounds of the present invention are useful as an elastase release inhibitor.

摘要翻译： 由下式（I）表示的羟基二十碳烯酸类似物，该键代表顺式亚乙烯基或亚乙炔基; Y代表CH 2，O或S（O）p，其中p是0,1或2; m表示1〜4的整数， n表示0〜3的整数， m和n的总和是3〜7的整数， R1代表C1-4烷基或C3-8环烷基; R2代表氢原子或甲基; R3代表COR4，腈基，卤素原子，四唑基或噻唑烷二酮基; R4代表OR6，NHR6，N（OH）R6 6，NHSO2R5，甘油或官能化甘油; R5代表C 1-15？ 烷基，被烷基，卤素或氨基取代的C 6-10芳基或C 7-14芳基; R 6表示氢，C 1-10 - 烷基或被羟基取代的C1-10烷基，或其药学上可接受的盐或水合物。 本发明的化合物可用作弹性蛋白酶释放抑制剂。